Does apixaban improve safety outcomes (bleeding rates) compared to warfarin in patients with end-stage renal disease?
Apixaban showed similar bleeding rates to warfarin in end-stage renal disease patients, suggesting it may be a cautious alternative.
There were no observed differences in bleeding rates in patients receiving apixaban compared with those receiving warfarin. Apixaban may be a cautious consideration in hemodialysis patients until there is further insight into the effect of subsequent, multiple doses on drug accumulation and clinical outcomes.
Sarratt et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: